Influenza - Wiki-CORONA

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
BTC and MMP9	betacellulin	matrix metallopeptidase 9	Signaling by ERBB2 Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PI3K events in ERBB4 signaling SHC1 events in ERBB4 signaling Nuclear signaling by ERBB4 PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma Constitutive Signaling by Aberrant PI3K in Cancer Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Downregulation of ERBB2 signaling Extra-nuclear estrogen signaling Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 TMD/JMD mutants	Signaling by SCF-KIT Collagen degradation Collagen degradation Degradation of the extracellular matrix Degradation of the extracellular matrix Activation of Matrix Metalloproteinases Assembly of collagen fibrils and other multimeric structures EPH-ephrin mediated repulsion of cells Interleukin-4 and Interleukin-13 signaling Neutrophil degranulation Extra-nuclear estrogen signaling		Glutathione Marimastat Minocycline Captopril Glucosamine Zinc 2-Amino-N,3,3-Trimethylbutanamide 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid AE-941 PG-530742 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID		Penile cancer Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
BTK and PIP4K2A	Bruton tyrosine kinase	phosphatidylinositol-5-phosphate 4-kinase type 2 alpha	ER-Phagosome pathway MyD88:MAL(TIRAP) cascade initiated on plasma membrane Regulation of actin dynamics for phagocytic cup formation DAP12 signaling FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization G alpha (q) signalling events G alpha (12/13) signalling events MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) RHO GTPases Activate WASPs and WAVEs G beta:gamma signalling through BTK FCGR3A-mediated phagocytosis Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Synthesis of PIPs at the plasma membrane PI5P Regulates TP53 Acetylation PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Synthesis of PIPs in the nucleus	Dasatinib Inositol 1,3,4,5-Tetrakisphosphate XL418 Ibrutinib Acalabrutinib		Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8 Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
BYSL and TEKT1	bystin like	tektin 1	Major pathway of rRNA processing in the nucleolus and cytosol
BYSL and L3MBTL3	bystin like	L3MBTL histone methyl-lysine binding protein 3	Major pathway of rRNA processing in the nucleolus and cytosol
C1R and TUBGCP2	complement C1r	tubulin gamma complex associated protein 2	Initial triggering of complement Classical antibody-mediated complement activation Regulation of Complement cascade	Recruitment of mitotic centrosome proteins and complexes Recruitment of NuMA to mitotic centrosomes	Cetuximab Etanercept Adalimumab Abciximab Gemtuzumab ozogamicin Trastuzumab Rituximab Basiliximab Muromonab Ibritumomab tiuxetan Tositumomab Alemtuzumab Alefacept Efalizumab Natalizumab Palivizumab Daclizumab Bevacizumab Zinc Human C1-esterase inhibitor Conestat alfa		Classic complement pathway component defects, including the following eight diseases: C1q alpha-chain deficiency; C1q beta-chain deficiency; C1q gamma-chain deficiency; C1r deficiency; C1s deficiency; C2 deficiency; C3 deficiency; C4 deficiency
CAPS and ACSL3	calcyphosine	acyl-CoA synthetase long chain family member 3		Intracellular metabolism of fatty acids regulates insulin secretion Synthesis of very long-chain fatty acyl-CoAs	Calcium Citrate Calcium Phosphate	Icosapent
CCNG1 and HMBOX1	cyclin G1	homeobox containing 1	Regulation of TP53 Degradation
CCNG1 and CDKN2A	cyclin G1	cyclin dependent kinase inhibitor 2A	Regulation of TP53 Degradation	Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1 Transcriptional Regulation by VENTX Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Apoptotic factor-mediated response Oxidative Stress Induced Senescence Oncogene Induced Senescence SUMOylation of DNA damage response and repair proteins SUMOylation of transcription factors Regulation of TP53 Degradation Stabilization of p53 Regulation of RUNX3 expression and activity Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function Evasion of Oncogene Induced Senescence Due to p14ARF Defects Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects				Bladder cancer Type II diabetes mellitus Pancreatic cancer Burkitt lymphoma Adult T-cell leukemia Malignant pleural mesothelioma Non-small cell lung cancer Chronic myeloid leukemia (CML) Oral cancer Penile cancer Nasopharyngeal cancer Glioma Osteosarcoma Squamous cell carcinoma Cholangiocarcinoma Gallbladder cancer Malignant islet cell carcinoma Laryngeal cancer Hepatocellular carcinoma Esophageal cancer Malignant melanoma
CCNG1 and PPP2CA	cyclin G1	protein phosphatase 2 catalytic subunit alpha	Regulation of TP53 Degradation	Inhibition of replication initiation of damaged DNA by RB1/E2F1 Spry regulation of FGF signaling Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal Integration of energy metabolism PP2A-mediated dephosphorylation of key metabolic factors DARPP-32 events Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade ERK/MAPK targets ERKs are inactivated MASTL Facilitates Mitotic Progression Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion Initiation of Nuclear Envelope (NE) Reformation CTLA4 inhibitory signaling Platelet sensitization by LDL Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane Misspliced GSK3beta mutants stabilize beta-catenin S33 mutants of beta-catenin aren't phosphorylated S37 mutants of beta-catenin aren't phosphorylated S45 mutants of beta-catenin aren't phosphorylated T41 mutants of beta-catenin aren't phosphorylated APC truncation mutants have impaired AXIN binding AXIN missense mutants destabilize the destruction complex Truncations of AMER1 destabilize the destruction complex RHO GTPases Activate Formins RAF activation Negative regulation of MAPK pathway Regulation of TP53 Degradation PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Mitotic Prometaphase Cyclin D associated events in G1 Cyclin A/B1/B2 associated events during G2/M transition Regulation of glycolysis by fructose 2,6-bisphosphate metabolism EML4 and NUDC in mitotic spindle formation Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)		Vitamin E 2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid (2S,3S,4E,6E,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid
CCNG1 and GAK	cyclin G1	cyclin G associated kinase	Regulation of TP53 Degradation	Golgi Associated Vesicle Biogenesis Clathrin-mediated endocytosis
CCNG1 and RBPMS	cyclin G1	RNA binding protein, mRNA processing factor	Regulation of TP53 Degradation
CCNG1 and PNMA1	cyclin G1	PNMA family member 1	Regulation of TP53 Degradation
CCNG1 and LMNA	cyclin G1	lamin A/C	Regulation of TP53 Degradation	XBP1(S) activates chaperone genes Signaling by BRAF and RAF fusions				Restrictive dermopathy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Mandibuloacral dysplasia Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy Limb-girdle muscular dystrophy (LGMD) Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Hutchinson-Gilford progeria syndrome
CCNG1 and MT-CO2	cyclin G1	cytochrome c oxidase subunit II	Regulation of TP53 Degradation	TP53 Regulates Metabolic Genes Respiratory electron transport		Cholic Acid N-Formylmethionine Talmapimod
CCNG1 and NFATC4	cyclin G1	nuclear factor of activated T cells 4	Regulation of TP53 Degradation
CCNG1 and CBY2	cyclin G1	chibby family member 2	Regulation of TP53 Degradation
CCNG1 and PAK5	cyclin G1	p21 (RAC1) activated kinase 5	Regulation of TP53 Degradation	Activation of RAC1
CCNG1 and KRT40	cyclin G1	keratin 40	Regulation of TP53 Degradation	Keratinization Formation of the cornified envelope
CCNG1 and PLEKHA4	cyclin G1	pleckstrin homology domain containing A4	Regulation of TP53 Degradation	Synthesis of PIPs at the plasma membrane		Inositol 1,3,4,5-Tetrakisphosphate
CCNG1 and TNIP1	cyclin G1	TNFAIP3 interacting protein 1	Regulation of TP53 Degradation	Ovarian tumor domain proteases

Search Results for: Influenza